China Nuokang receives SFDA manufacturing license for Dipyridamole Aspirin

China Nuokang Bio-Pharmaceutical Inc. (Nasdaq:NKBP) ("Nuokang" or the "Company"), a leading China-based biopharmaceutical company focused on the research, development, manufacture, marketing and sales of hospital-based medical products, today announced that the Company has received the manufacturing license from the State Food and Drug Administration ("SFDA") for Dipyridamole Aspirin, a stroke-prevention product developed in-house. The Company expects to begin marketing this product in the second quarter of 2011 after completing its production and sales preparation process.

Baizhong Xue, the Company's Chairman and CEO, commented, "We are so pleased with our continued progress diversifying our product portfolio, which will bring us closer to our goal of becoming one of China's leading diversified biopharmaceutical companies. With Dipyridamole Aspirin, as well as with the imported cardiovascular product for which we recently acquired exclusive marketing rights in China, we expect to further expand our strong distribution capabilities beyond inpatient product channels. In fact, we already began building out a specialized sales and marketing team focused on outpatient cardiovascular products."